# TheraLens: Review-3 Final Implementation Status Report

**Project Title:** TheraLens: Machine Learning-Based Forecasting of Emerging Diseases and Future Therapeutic Development  
**Academic Milestone:** VIT Applied Machine Learning — Review-3 (100% Final Submission)  
**Date of Sign-Off:** October 2026  
**Project Team:**
- **S. Yuvaresh** (`24BCS0195`) — School of Computer Science and Engineering
- **M. Gopika** (`24BCA0243`) — School of Computer Science and Engineering
**Faculty Supervisor:** **Dr. M. Parimala**, Professor, Department of Computer Science and Engineering  
**Institution:** Vellore Institute of Technology (VIT), Vellore Campus  

---

## 1. Executive Summary & Review-3 Sign-Off

The TheraLens Applied Machine Learning project has achieved **100% implementation completion**, satisfying all university Review-3 rubrics, software engineering criteria, scientific rigor standards, and documentation requirements.

All 6 core pipeline subsystems are fully implemented, executed without fatal errors against local datasets, verified via a 26-test automated test suite (100% pass rate), supported by 20 verifiable output artifacts, documented in a 9-page university report conforming to the $\le 15$ page limit, and accompanied by a comprehensive viva defense guide.

---

## 2. What Was Already Implemented

Prior to this Review-3 finalization cycle, the repository contained the foundation from Review-1 and Review-2 (~82.5% internal progress):
1. **Raw Dataset Collection**: Heterogeneous biomedical datasets from WHO, Open Targets, ChEMBL, and FDA Drugs@FDA. Raw ChEMBL files reflect 8,023 bioactivity records and 6,319 small molecules (filtered from an initial query of 22,238 records and 8,983 candidate compounds).
2. **Symptom Deduplication Prototype**: Identification of 4,657 identical rows in `symptom_disease.csv` and extraction of 304 unique patterns.
3. **Core ML Classifier**: Multinomial Logistic Regression, Random Forest, SVM, and Dummy baseline on deduplicated symptom data.
4. **Candidate Prioritization Logic**: Multi-attribute scoring combining Open Targets, pChEMBL potency, Lipinski rules, and clinical phases.
5. **Surveillance & Anomaly Detection**: Standardization of WHO Measles, Yellow Fever, and Cholera datasets with rolling Z-score surge detection.
6. **Timeline Integration Stream**: Large-scale join producing 555k master timeline records and mapping audit.
7. **Basic Pytest Suite**: 15 tests verifying primary schemas and basic pipeline functions.

---

## 3. What Was Changed & Implemented for Review-3

During this Review-3 completion cycle, the following enhancements and deliverables were completed:

1. **Fast Fixture & Edge-Case Test Suite (`tests/test_unit_and_pipeline_fixtures.py`)**:
   - Expanded the test suite from 15 to **26 unit and integration tests**.
   - Added unit tests for symptom vectorizer whitespace, mixed casing, and unmapped inputs.
   - Added molecular boundary tests for Lipinski & Veber rules ($MW=500.0$ vs $500.1$, $ALogP=5.0$ vs $5.01$).
   - Added mathematical formula verification for Composite Priority Score ($CPS$) weights summing strictly to $1.00$.
   - Added zero-denominator stability tests for epidemiological MAPE calculations.
   - Added flat time-series tests confirming zero false-positive outbreak surges.
   - Added pharmaceutical ingredient normalization and salt suffix stripping tests.
   - Added biopharmaceutical milestone transition latency unit tests.
   - Added negative control biological audit test (Medroxyprogesterone Acetate / AIDS / PGR).
   - Added lightweight in-memory pipeline mock tests.

2. **Robust Software Decoupling & Warning Fixes**:
   - Made `requests` optional in `src/data_processing/build_therapeutic_timeline.py` with graceful error handling, ensuring offline execution works out-of-the-box using local datasets and pre-computed SQLite caches.
   - Fixed Seaborn v0.14 `palette`-without-`hue` deprecation warnings in visualization routines.
   - Accurately documented the scikit-learn 1.9 `SVC(probability=True)` deprecation notice as non-fatal library output, preserving the serialized production Logistic Regression model.

3. **Master Pipeline Execution & Verification**:
   - Successfully executed `src/run_theralens.py` across all 6 core modules in ~37 seconds with **zero fatal errors**.
   - Verified disease prediction CLI uncalibrated score of 0.2794 for presenting symptoms (`chills, vomiting, high_fever, sweating, headache`).
   - Generated and validated all 20 production artifacts under `outputs/`, `models/`, and `data/processed/`.

4. **Updated Comprehensive `README.md`**:
   - Upgraded documentation to 100% Review-3 standard with exact CLI execution commands, full directory tree, verified metrics, and scientific disclaimers.

5. **Authored Official VIT Review-3 Final Report (`docs/theralens_review3_report.md` & `.pdf`)**:
   - Formatted strictly according to VIT's prescribed 8-section template.
   - Rendered to HTML (`docs/theralens_review3_report.html`) and compiled to PDF (`docs/theralens_review3_report.pdf`).
   - Verified exact page count: **9 pages** (strictly $\le 15$ pages).

6. **Authored University Viva Voce Defense Guide (`docs/theralens_review3_viva.md`)**:
   - Prepared detailed answers to challenging examiner questions regarding 100% benchmark accuracy, baseline superiority in non-stationary time series, negative controls, Cartesian join disambiguation, and a 3-step live demonstration script.

7. **Project Auditing & Tracking**:
   - Created `docs/REVIEW3_COMPLETION_AUDIT.md` documenting gap resolution across all subsystems.
   - Created this final status report (`docs/REVIEW3_FINAL_STATUS.md`).

8. **FDA–ChEMBL Entity Matching Reconciliation**:
   - Verified exact numbers against `data/processed/fda_chembl_match_audit.csv` and `outputs/timeline_analysis/mapping_audit_summary.json`.
   - Ingredients evaluated: **3,142** unique FDA active ingredients (from 12,243 approved product records).
   - Ingredients matched: **3,059** (exact preference name: 2,147; multi-component combination: 599; synonym: 299; partial combination: 9; salt-stripped: 5).
   - Ingredients unmatched: **83**.
   - Resulting empirical match rate: $\frac{3059}{3142} = \mathbf{97.36\%}$.

---

## 4. Automated Testing & Verification Outcomes

- **Test Framework**: `pytest` 9.1.1 running on Python 3.12.10.
- **Execution Command**: `pytest -v`
- **Result**: **26 passed in 4.44s (100% Pass Rate)**

```
tests/test_epidemiological_analysis.py::test_epidemiological_trends_dataset PASSED [  3%]
tests/test_epidemiological_analysis.py::test_missing_value_retention PASSED [  7%]
tests/test_epidemiological_analysis.py::test_outbreak_surge_detection_logic PASSED [ 11%]
tests/test_symptom_classifier.py::test_raw_symptom_dataset_schema PASSED [ 15%]
tests/test_symptom_classifier.py::test_deduplication_and_unique_patterns PASSED [ 19%]
tests/test_symptom_classifier.py::test_leakage_free_train_test_split PASSED [ 23%]
tests/test_symptom_classifier.py::test_persisted_model_reproducibility PASSED [ 26%]
tests/test_symptom_classifier.py::test_inference_predictor_api PASSED    [ 30%]
tests/test_therapeutic_prioritization.py::test_input_schemas_and_identifiers PASSED [ 34%]
tests/test_therapeutic_prioritization.py::test_druglikeness_scoring_logic PASSED [ 38%]
tests/test_therapeutic_prioritization.py::test_clinical_evidence_bonus_logic PASSED [ 42%]
tests/test_therapeutic_prioritization.py::test_candidate_rankings_output_integrity PASSED [ 46%]
tests/test_timeline_validation.py::test_fda_timeline_schema PASSED       [ 50%]
tests/test_timeline_validation.py::test_fda_chembl_matching_rate PASSED  [ 53%]
tests/test_timeline_validation.py::test_evidence_classification_audit PASSED [ 57%]
tests/test_unit_and_pipeline_fixtures.py::test_symptom_vectorizer_edge_cases PASSED [ 61%]
tests/test_unit_and_pipeline_fixtures.py::test_feature_consistency_between_training_and_inference PASSED [ 65%]
tests/test_unit_and_pipeline_fixtures.py::test_druglikeness_exact_boundaries PASSED [ 69%]
tests/test_unit_and_pipeline_fixtures.py::test_clinical_evidence_bonus_comprehensive PASSED [ 73%]
tests/test_unit_and_pipeline_fixtures.py::test_composite_priority_score_mathematical_weights PASSED [ 76%]
tests/test_unit_and_pipeline_fixtures.py::test_drug_normalization_and_salt_stripping PASSED [ 80%]
tests/test_unit_and_pipeline_fixtures.py::test_milestone_forecast_durations_and_success_rates PASSED [ 84%]
tests/test_unit_and_pipeline_fixtures.py::test_epidemiological_metric_zero_denominator_protection PASSED [ 88%]
tests/test_unit_and_pipeline_fixtures.py::test_surge_detector_flat_series_no_false_alarm PASSED [ 92%]
tests/test_unit_and_pipeline_fixtures.py::test_negative_control_medroxyprogesterone_audit PASSED [ 96%]
tests/test_unit_and_pipeline_fixtures.py::test_lightweight_prioritization_mock PASSED [100%]
============================= 26 passed in 4.44s ==============================
```

---

## 5. Master Pipeline Execution Verification

- **Command Executed**: `python src/run_theralens.py`
- **Execution Time**: **37.17 seconds**
- **Outcome**: **100% SUCCESS** across all 6 modules:
  - `symptom_classifier`: SUCCESS (9.55s)
  - `therapeutic_prioritization`: SUCCESS (4.72s)
  - `epidemiological_analysis`: SUCCESS (3.00s)
  - `timeline_validation`: SUCCESS (7.22s)
  - `experimental_forecast`: SUCCESS (2.42s)
  - `explainability`: SUCCESS (10.26s)
- **Summary File Generated**: `outputs/run_pipeline_summary.json`

---

## 6. Generated Production Artifacts

All 20 master artifacts are present, valid, and non-empty:

| # | Artifact Path | Size / Rows | Verification Status | Description |
| :-: | :--- | :---: | :---: | :--- |
| 1 | `models/symptom_classifier.joblib` | 45.2 KB | Verified | Persisted best Logistic Regression pipeline |
| 2 | `models/symptom_classifier_metadata.json` | 1.45 KB | Verified | Training, test, and CV performance metadata |
| 3 | `models/feature_names.json` | 2.84 KB | Verified | 132 symptom feature names |
| 4 | `models/class_labels.json` | 796 B | Verified | 41 disease prognosis class labels |
| 5 | `outputs/model_evaluation/model_comparison.csv` | 278 B | Verified | Metrics table comparing 4 candidate models |
| 6 | `outputs/model_evaluation/confusion_matrix.png` | 1.56 MB | Verified | 41-class diagonal test confusion matrix |
| 7 | `data/processed/symptom_disease_clean.csv` | 304 rows | Verified | Deduplicated unique presentation manifold |
| 8 | `data/processed/disease_target_rankings.csv` | 3,636 rows | Verified | Open Targets disease-target rankings |
| 9 | `data/processed/therapeutic_candidate_rankings.csv` | 25,650 rows | Verified | Candidate molecules ranked by Composite Score ($CPS$) |
| 10 | `outputs/therapeutic_prioritization/top_candidate_scores.png` | 285 KB | Verified | Diagnostic bar chart of top candidates per disease |
| 11 | `outputs/therapeutic_prioritization/score_component_breakdown.png`| 235 KB | Verified | Stacked multi-attribute score decomposition plot |
| 12 | `data/processed/epidemiological_trends.csv` | 5,426 rows | Verified | Standardized long-format WHO surveillance records |
| 13 | `outputs/epidemiological_analysis/global_incidence_trends.png` | 274 KB | Verified | 51-year longitudinal Measles & Yellow Fever incidence |
| 14 | `outputs/epidemiological_analysis/forecasting_model_comparison.png`| 294 KB | Verified | Time-ordered forecast curves vs actual reported cases |
| 15 | `outputs/timeline_analysis/timeline_quality_report.txt` | 2.31 KB | Verified | Regulatory audit text report |
| 16 | `outputs/timeline_analysis/mapping_audit_summary.json` | 1.88 KB | Verified | Entity resolution match breakdown and Cartesian audit |
| 17 | `outputs/timeline_analysis/timeline_evidence_classification.png` | 123 KB | Verified | Chart classifying Phase 4 approvals vs investigational trials |
| 18 | `outputs/timeline_analysis/experimental_forecast_projections.csv`| 37 diseases| Verified | Biopharmaceutical milestone decision windows |
| 19 | `outputs/timeline_analysis/forecast_pipeline_latencies.png` | 403 KB | Verified | Latency milestone projections with 80% CI error bars |
| 20 | `outputs/explainability/symptom_permutation_importance.csv` | 132 rows | Verified | Permutation importance values over 20 repeats |

---

## 7. Report Compliance & Page Constraint Verification

- **Document Location**: `docs/theralens_review3_report.md`
- **Compiled PDF**: `docs/theralens_review3_report.pdf`
- **Compiler**: `docs/build_review3_report.py` (Markdown $\to$ HTML $\to$ Edge Headless print-to-pdf)
- **Measured Page Count via `pypdf`**: **9 pages**
- **Template Requirement**: Must contain no more than 15 pages.
- **Verdict**: **STRICTLY COMPLIANT** (9 pages $\le 15$ pages).

---

## 8. Unresolved Issues & Manual Actions

- **Unresolved Technical Defects**: **None**. All code compiles, runs cleanly, passes all tests, and handles edge cases gracefully.
- **Unresolved Data Gaps**: **None**. All raw and processed datasets are present locally; offline execution does not depend on external network access or paid credentials.
- **Manual Actions Required by Team**:
  1. Print or submit `docs/theralens_review3_report.pdf` according to VIT review submission guidelines.
  2. Review `docs/theralens_review3_viva.md` to rehearse presentation talking points and live terminal commands.
  3. No additional code modification is required.
